skip to main content
Idioma:

Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain

Roitberg, F. ; Amaral, T. ; Cherny, N.I. ; Giuliani, R. ; Latino, N.J. ; Galotti, M. ; Bricalli, G. ; Curigliano, G. ; Pentheroudakis, G. ; Trapani, D.

ESMO open, 2023-10, Vol.8 (5), p.101617-101617, Article 101617 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
  • Título:
    Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain
  • Autor: Roitberg, F. ; Amaral, T. ; Cherny, N.I. ; Giuliani, R. ; Latino, N.J. ; Galotti, M. ; Bricalli, G. ; Curigliano, G. ; Pentheroudakis, G. ; Trapani, D.
  • Assuntos: cancer medicines ; ESMO-MCBS ; Global cancer policy ; Original Research ; value in health ; WHO Model List of Essential Medicines
  • É parte de: ESMO open, 2023-10, Vol.8 (5), p.101617-101617, Article 101617
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    Co-first authors.
  • Descrição: Cancer is a global public health problem, requiring efficient health system investments to deliver sustainable impact on population health. Access to medicines is a critical component of health systems, having a crucial role in delivering therapeutic benefits. Since 1977, the World Health Organization (WHO) has published a Model List of Essential Medicines (EML) that includes key health interventions for the prevention and control of conditions of public health relevance. Essential medicines are selected for inclusion in the EML based on the evidence of efficacy, safety, therapeutic value, and the potential to impact population health. With the rapid changes in the therapeutic landscape of cancer treatment with new medicine approvals, there is a critical need to select and prioritise specific cancer interventions based on their intrinsic value. The European Society for Medical Oncology (ESMO) has developed a decisional methodology based on a threshold with a minimum set of technical specifications and a consensus-based procedure for decisions to select candidate cancer medicines to be submitted to the WHO for consideration for the WHO EML. ESMO recognises the WHO EML as an important reference guide for medicines that all countries should include in their national EMLs. Cancer medicines on the WHO EML are used in the treatment of the majority of cancers, and are recommended in the evidence-based ESMO Clinical Practice Guidelines that medical oncologists use to treat patients. ESMO’s submissions to the WHO EML in 2019 and 2021 and their respective outcomes are presented in the manuscript. Due to the rising costs associated with newly available therapies, structured, reproducible, and field-tested tools to evaluate the added clinical benefit from these therapies need to be implemented in pre-selecting potential candidate medicines to be included in the WHO EML. ESMO is proud to collaborate closely with WHO on this important global public health initiative. •Prioritising access to safe, effective, quality, and affordable essential medicines is key to improve cancer care.•The WHO is instrumental in recognising medicines with public health relevance through the WHO Essential Medicines’ List.•EML’s selection is based on disease prevalence, evidence of efficacy and safety, and comparative cost-effectiveness.•The WHO EML Expert Committee recognises the ESMO-MCBS as a screening tool for inclusion consideration in the EML.•ESMO supports the update of the WHO EML, a reference for countries to ensure essential cancer care to all.
  • Editor: Elsevier Ltd
  • Idioma: Inglês
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  3 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.